Testagen

Overview

Testagen is a synthetic tetrapeptide — Lys-Glu-Asp-Gly ("KEDG") — from Vladimir Khavinson's family of "short peptide bioregulators," developed in the Russian/CIS tradition associated with the St. Petersburg Institute of Bioregulation and Gerontology. It is marketed toward testicular/testosterone and thyroid "support" with a proposed epigenetic gene-regulation mechanism.

Its chemistry is reasonably well defined by convergent sources: molecular formula C17H29N5O9, average molecular weight 447.44 g/mol (independently recomputed from Lys + Glu + Asp + Gly − 3 H2O), all-L (natural) stereochemistry. The structure H-Lys-Glu-Asp-Gly-OH is independently corroborated by a 2025 Molecules paper — though that study is chemistry (copper-corrosion inhibition), not biology.

The honest evidence picture is thin, older, and mostly Russian. The actual PubMed-indexed primary work is animal — thyroid structure and hormonal activity in neonatally hypophysectomised chickens and old hens (Bull Exp Biol Med 2008 and 2011) — plus in-vitro data that short Khavinson peptides can enter cell nuclei and bind DNA/oligonucleotides (Biochemistry (Moscow) 2011). Vendor "boosts testosterone / testes bioregulator" framing outruns the published biology, which is largely about the thyroid. There are no PubMed-indexed human trials, no pharmacokinetic or toxicology data, and no FDA/EMA approval. It is sold only as a research chemical.

Chemistry and structure

The molecular weight was independently recomputed from the constituent amino acids (Lys + Glu + Asp + Gly − 3 H2O) and agrees with vendor listings and the 2025 Molecules paper. No PubChem compound record could be located for this exact peptide, so the formula/weight rest on independent calculation plus source agreement rather than a PubChem canonical record. The CAS number 1026993-38-3 is vendor-listed only (e.g. BOC Sciences) and does not resolve in PubChem's cross-reference registry — it should be treated as unverified. Monoisotopic mass and canonical SMILES/InChI were not retrieved from a primary chemistry database.

Mechanism of action

• DNA/chromatin interaction and gene-expression modulation — as a short peptide, Testagen is proposed to penetrate the cell and nuclear membranes and interact directly with DNA/chromatin to modulate gene expression (the general Khavinson "peptide bioregulator" epigenetic hypothesis). [In vitro] (Short fluorescently-labeled Khavinson peptides shown to enter HeLa cell nuclei and bind deoxyribo-oligonucleotides/DNA in vitro — Biochemistry (Moscow) 2011, PMID 22117547. Mechanistic only; does not demonstrate a specific clinical effect.)
• Modulation of thyroid structure and hormonal activity — partially corrects hypophysectomy-induced thyroid atrophy, with a greater effect in younger animals. [Animal] (Bull Exp Biol Med 2008 PMID 19024016 and 2011 PMID 22268052; Adv Gerontol 2011 PMID 21809626, Russian; Patol Fiziol Eksp Ter 2010 PMID 20731122, Russian — all in hypophysectomised birds; small, single-group, mostly Russian.)
• Regulation of testicular steroidogenesis / testosterone synthesis — the marketed rationale (the name derives from testis). [Hypothesis] (No PubMed-indexed study demonstrating a testosterone/steroidogenesis effect was found; the verifiable animal biology is thyroid-focused. Treat as vendor hypothesis.)

Research and evidence

Human evidence. No PubMed-indexed human clinical trials were found. Peptide-vendor pages cite a single small controlled report (~36 men with chronic abacterial prostatitis and androgen deficiency, "Testagen" as a testosterone-synthesis inductor, said to be published in a Russian/Ukrainian endocrinology journal), but this citation could not be located or verified in any primary index — no PMID, authors, or year confirmable. Treat human efficacy as unverified/anecdotal [Human]. In short: no well-established human clinical trials. Human dosing, pharmacokinetics (bioavailability, half-life, metabolism, clearance), and toxicology are not established in any verifiable source; vendor "protocols" are not evidence-based.

Status and regulation

Testagen is not approved by the FDA or EMA for any indication, and there is no evidence of a licensed product in any jurisdiction. It is of Russian/CIS origin (developed in the Khavinson tradition at the St. Petersburg Institute of Bioregulation and Gerontology) and is sold only as a research-use-only reagent by peptide vendors. Any human use would make it an unauthorised (unlicensed) medicine — "no specific ban" is not affirmative permission.

WADA status: no source was found addressing whether Testagen is on the WADA Prohibited List, so no class code is stated here. WADA sport-prohibition is a separate axis from legality; do not infer a code from its unapproved status.

Safety

• Human safety profile is not established in verifiable sources — no toxicology, reproductive-toxicity, pharmacokinetic, or drug-interaction data of adequate quality were found.
• The reported biological effects come from animal (bird) and in-vitro models, which do not establish safety in humans.
• Material sold as a research reagent is not a quality-controlled medicine and may vary in identity, purity, and sterility.
• No human dosing has been established; any human use is experimental and unsupervised by design. Vendor dosing charts are not backed by clinical evidence.

Legal status

Testagen's regulatory classification is a research reagent ("research use only") — it is not approved for human use in the US or EU, and no licensed product was identified in any jurisdiction. "No specific ban" is not affirmative permission: a compound becomes an unauthorised medicine the moment it is intended for human use, regardless of how it is labeled at point of sale. Its Russian/CIS origin does not confer legality elsewhere. Regulatory status differs by country and can change. This is not legal advice — verify the status in your own jurisdiction. (Dated 2026-07-08.)

How it compares

• Epitalon — another Khavinson "short peptide bioregulator" and a synthetic tetrapeptide (Ala-Glu-Asp-Gly, AEDG), sharing Testagen's pattern of bold claims resting on the same research lineage with limited independent replication and no robust human trials.
• Cortagen — a related Khavinson-school tetrapeptide (Ala-Glu-Asp-Pro) marketed for a different organ system (brain/nerve), illustrating the same "one peptide per tissue" bioregulator framing that outruns its published biology.
• Gonadorelin — by contrast, a well-characterised hypothalamic decapeptide (GnRH) with an established endocrine mechanism and approved clinical uses — a useful reference point for how much weaker the Testagen evidence base is on the reproductive/hormonal axis.

Common misconceptions

• "Testagen boosts testosterone — it's proven." No PubMed-indexed study demonstrates a testosterone or steroidogenesis effect. The testes/testosterone framing is a vendor hypothesis [Hypothesis]; the verifiable animal biology is about the thyroid [Animal].
• "There's a human study showing it works." The vendor-cited prostatitis/androgen study (~36 men) could not be verified — no PMID, authors, year, or journal confirmable. Treat human efficacy as unverified [Human].
• "Its CAS number is 1026993-38-3." That is a vendor-listed number that does not resolve in PubChem; there is no PubChem compound record for this exact peptide. Treat the CAS as unverified.
• "It regulates genes by binding DNA in the body." Nuclear penetration and DNA binding are in-vitro observations for short Khavinson peptides [In vitro]; the epigenetic gene-regulation mechanism is a hypothesis, not a demonstrated physiological effect in humans.
• "Not banned means legal to take." No specific ban is not affirmative permission; Testagen is a research reagent and becomes an unauthorised medicine the moment it is intended for human use.